Doximity Earnings: Strong AI Signals, But Monetization Still Pending

Doximity posted mixed FY26 results: revenue growth remains solid, but margins compressed and FY27 guidance calls for just 4% revenue growth with additional EBITDA margin pressure. AI-driven engagement is scaling quickly, with strong adoption of clinical tools and enterprise traction, but monetisation is being held back by regulatory and operational friction. The outlook implies FY27 will be a transition year as AI investment ramps.

Analysis

The key issue is not the near-term revenue print; it is that AI is currently functioning more as a top-of-funnel engagement engine than a monetizable product cycle. That creates a classic second-order risk for software multiples: usage metrics improve while near-term cash conversion worsens because the company has to fund compute, product development, and go-to-market before pricing power is proven. In healthcare, that gap can last longer than in other vertical SaaS names because workflow integration, compliance review, and procurement cycles slow conversion from experimentation to paid expansion.

Competitive dynamics likely favor the largest incumbent platforms with the deepest distribution and regulatory infrastructure, even if smaller specialists show better product novelty. If customers are adopting AI tools broadly but delaying monetization, the market may eventually reward whichever vendor can bundle AI into existing contracts with minimal incremental friction. That argues for share gains among incumbents with stronger enterprise relationships, while pure-play monetization stories face the risk of being valued on engagement but delivered on ARR.

The next 1-2 quarters are the critical window: if margin pressure steepens as AI investment ramps without a corresponding lift in enterprise bookings, the stock can derate on a forward-growth reset rather than on absolute fundamentals. The contrarian point is that the market may already be pricing the transition-year narrative, which means the asymmetry shifts toward operational proof rather than disappointment. Any evidence of faster attach rates, higher seat expansion, or lower sales-cycle friction would be the main catalyst to reverse the bear case, while continued guidance conservatism keeps the multiple capped.

On the tape, this is a better short-on-rallies than an outright momentum short because the business still has defensive healthcare exposure and a credible AI story that can support sentiment spikes. The cleaner expression is relative-value versus higher-duration software names where AI spend is less tied to regulated workflows and monetization is more immediately visible.

Key Decisions for Investors

• Short DOCS on strength over the next 2-6 weeks if the market bids the AI narrative without a guide-up in monetization; use a tight stop above the post-earnings high because the stock can squeeze on any product-announcement follow-through.
• Pair trade: long a profitable healthcare software incumbent vs short DOCS over 1-3 months to isolate monetization risk from AI hype risk; the long leg should have clearer cash-flow conversion and less guidance dispersion.
• Buy DOCS downside via 3-6 month put spreads rather than outright puts; the risk/reward improves if margin compression persists, while limiting theta bleed if the stock grinds sideways on AI enthusiasm.
• Wait for the next quarterly update before adding long exposure; only step in if enterprise adoption translates into visible paid conversion metrics, since that is the earliest inflection point for re-rating.
• If DOCS weakens further on stable engagement data, cover part of the short and rotate to a smaller tactical short in higher-multiple software names with weaker visibility, as DOCS may become the cleaner quality name once expectations reset.